@bmprii Congratulations to you and the team! Excited for our field and our patients. I hope you use your position to “fact-check” misleading news articles suggesting that sotatercept is a reversal agent. You would agree that it hasn’t been tested although we all have opinions it may
Incredible. Hats off to all scientists/investigators/patients(!). Excited to have access to therapy w such a potential. BUT!!!! Inaccurate& misleading news will NOT help our field or patients. Opinion is not fact! @PVRI@Viniciodjperez@AlbertaPHdoc
https://t.co/bZ8ypxtcCF
A pleasure to help pave to define disease modification in PAH. An honor to work with a superb group of colleagues - Exciting think-tank style collab, along with the ever-so-important patient perspective
https://t.co/2iYxrB1Cn0
@PHatStanford@AlbertaPHdoc@PVRI
Difficult news to hear….a huge loss for the field and our community. On behalf of @PHatStanford, our deepest condolences to the Newman family and Vanderbilt colleagues. His legacy will live on thru his contributions to our field and the many he has mentored.
The PVRI is deeply saddened by the loss of Dr John Newman, a cherished member of the Pulmonary Vascular Disease community. His dedication and expertise have left an indelible mark on our field. Sending heartfelt condolences to his loved ones and colleagues during this time.
RIP Major Brian Shul! Incredible story of an aviator. - resilience, courage, and grit. Spoke at our @PHatStanford pulmonary hypertension symposium a few years ago….
https://t.co/0Dm2JQ8t8u
Congratulations to Andy Sweatt & Adam Andruska for amazing presentations on vasoreactivity in PAH & PVOD risk score. Did us proud!! @ATS_PC@atscommunity@StanfordPACCM
@TamCardio@TamCardio was our honor to have you participate! After all we are neighbors (just across the small pond) 😭. Cheers to more collaborations and good discussions.